Tysabri® (natalizumab) Injection

Tysabri (natalizumab) is covered for adults (≥18) as monotherapy for relapsing forms of multiple sclerosis and for adults with moderately-to-severely active Crohn’s disease with evidence of inflammation after inadequate response or intolerance to conventional therapies including TNF‑α inhibitors. Coverage requires specialist prescribing/consultation (neurologist for MS, gastroenterologist for CD), specified prior therapy trials (≥1 MS DMT or ≥2 Crohn’s biologics), time‑limited approvals (MS 12 months; CD initial 6 months then 12‑month reauth), and objective evidence of benefit for reauthorization (clinical/MRI/lab/endoscopic measures); patients <18 are excluded.

"Multiple sclerosis (MS) — Tysabri is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and a..."